INVO Fertility receives patent allowance for modified INVOcell device

SARASOTA, Fla. - INVO Fertility, Inc. (Nasdaq:IVF), a micro-cap fertility technology company with a market capitalization of $2.16 million, has received a notice of allowance from the United States Patent and Trademark Office for a modified version of its INVOcell device, according to a company press release issued Wednesday.

The patent, titled "Intravaginal Culture Incubation Container and Method," extends intellectual property protection for the device through 2040. The modified design reflects feedback from embryologists who suggested simplifying the device by removing the separate microchamber in favor of a singular main chamber.

INVOcell is an FDA-cleared intravaginal culture system that allows fertilization and early embryo development to occur within a woman’s body. During the procedure, eggs and sperm are placed in the device, which is then inserted into the vaginal cavity for a 5-day incubation period before embryos are transferred to the uterus.

The device first received FDA clearance in 2015, with an updated clearance in 2023 that increased the incubation period from 3 to 5 days. While the company generated revenue of $6.59 million in the last twelve months, InvestingPro data shows significant cash burn and short-term liquidity challenges, with a current ratio of just 0.08.

"The receipt of a new patent for our simplified device expands our intellectual property protection," said Steve Shum, CEO of INVO Fertility, in the press release.

INVO Fertility currently operates two INVO Centers in the United States and one in vitro fertilization clinic. The company also sells and distributes its INVOcell technology to third-party fertility clinics.

The patent will be granted and published once the company pays the required issue fee.

In other recent news, INVO Fertility, Inc. has expanded its telehealth services at the Wisconsin Fertility Institute, allowing virtual consultations across nine states, including Illinois and Colorado. This expansion aims to improve access to fertility care, particularly for those in rural or underserved areas. Additionally, INVO Fertility has entered into a significant agreement with an institutional investor, issuing new warrants for approximately 698,760 shares of common stock. This transaction is expected to generate around $750,000 in gross proceeds for the company. Moreover, INVO Fertility received a Nasdaq delisting notice due to a late filing of its Annual Report for the fiscal year ended December 31, 2024. The company has until June 15, 2025, to submit a compliance plan. In a corporate update, the company, formerly known as NAYA Biosciences, Inc., has officially changed its name to INVO Fertility, Inc., with plans to update its Nasdaq trading symbol accordingly.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.